Jasper Therapeutics, Inc., (JSPR): Price and Financial Metrics
JSPR Price/Volume Stats
| Current price | $22.77 | 52-week high | $31.01 |
| Prev. close | $22.44 | 52-week low | $4.00 |
| Day low | $22.29 | Volume | 48,200 |
| Day high | $24.67 | Avg. volume | 113,788 |
| 50-day MA | $25.33 | Dividend yield | N/A |
| 200-day MA | $13.75 | Market Cap | 343.01M |
JSPR Stock Price Chart Interactive Chart >
Jasper Therapeutics, Inc., (JSPR) Company Bio
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company develops JSP191, a humanized monoclonal antibody for clearing hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It also develops Jasper eHSC Platform to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
Latest JSPR News From Around the Web
Below are the latest news stories about JASPER THERAPEUTICS INC that investors may wish to consider to help them evaluate JSPR as an investment opportunity.
Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)REDWOOD CITY, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell-driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced that, on December 14, |
Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023Stanford Medicine Presents Additional Positive Data from Investigator-Sponsored Phase 1b/2a Study of Briquilimab in Patients with Fanconi AnemiaREDWOOD CITY, Calif., Dec. 10, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as |
Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous UrticariaREDWOOD CITY, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell-driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced that the first patient h |
Jasper Therapeutics Inc (JSPR) Reports Q3 2023 Financial Results and Business ProgressKey Developments and Financial Highlights for Investors |
Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateREDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced results for the fiscal q |
JSPR Price Returns
| 1-mo | -24.10% |
| 3-mo | 31.16% |
| 6-mo | 229.81% |
| 1-year | 55.96% |
| 3-year | -77.05% |
| 5-year | N/A |
| YTD | 188.59% |
| 2023 | 63.39% |
| 2022 | -93.85% |
| 2021 | -21.58% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...